Overview

* Eledon reports Q3 net loss of $17.46 mln, compared to net income last year

* Company strengthens balance sheet with $57.5 mln financing for transplantation programs

Result Drivers

* Research and development (R&D) expenses for the third quarter of 2025 were $15.0 million, including $1.1 million of non-cash stock-based compensation expense

* FINANCIAL STRENGTH - $57.5 mln financing to advance transplantation programs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$17.46

Income mln

Q3 Basic -$0.21

EPS

Q3 -$19.07

Income mln

from

Operatio

ns

Q3 $19.07

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc ( ELDN ) is $9.00, about 80.4% above its November 13 closing price of $1.76

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)